3
|
Rujitharanawong C, Yoodee S, Sueksakit K, Peerapen P, Tuchinda P, Kulthanan K, Thongboonkerd V. Systematic comparisons of various markers for mast cell activation in RBL-2H3 cells. Cell Tissue Res 2022; 390:413-428. [PMID: 36125550 DOI: 10.1007/s00441-022-03687-w] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/10/2022] [Accepted: 09/08/2022] [Indexed: 11/30/2022]
Abstract
Mast cell activation plays a key role in various allergic diseases and anaphylaxis. Several methods/techniques can be used for detection of mast cell activation. However, there was no previous systematic evaluation to compare the efficacy of each method/technique. The present study thus systematically compared various markers for mast cell activation induced by IgE cross-linking. The widely used RBL-2H3 mast cells were sensitized with anti-DNP (dinitrophenyl) IgE overnight and activated with DNP-BSA (bovine serum albumin) for up to 4 h. The untreated cells and those with anti-DNP IgE sensitization but without DNP-BSA activation served as the controls. Intracellular calcium level gradually increased to ~2-fold at 1 h, reached its peak (~5-fold) at 2 h, and returned to the basal level at 3-h post-activation. The increases in cellular tryptase level (by Western blotting) (~0.3- to 0.4-fold) and average cell size (~2.5-fold) and decrease of nucleus/cytoplasm ratio (~0.4- to 0.5-fold) were marginal at all time-points. By contrast, β-hexosaminidase release and CD63 expression (by both flow cytometry and immunofluorescence detection/localization), secreted tryptase level (by Western blotting), and tryptase expression (by immunofluorescence detection/localization) stably and obviously increased (~10-fold as compared with the untreated control and sensitized-only cells or detectable only after activation). Based on these data, the stably obvious increases (by ≥ 10-fold) in β-hexosaminidase release, CD63 expression (by both flow cytometry and immunofluorescence staining), secreted tryptase level (by Western blotting), and tryptase expression (by immunofluorescence staining) are recommended as the markers of choice for the in vitro study of mast cell activation using RBL-2H3 cells.
Collapse
Affiliation(s)
- Chuda Rujitharanawong
- Department of Dermatology, Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok, Thailand
| | - Sunisa Yoodee
- Medical Proteomics Unit, Office for Research and Development, Faculty of Medicine Siriraj Hospital, Mahidol University, 6th Floor - SiMR Building, 2 Wanglang Road, Bangkoknoi, Bangkok, 10700, Thailand
| | - Kanyarat Sueksakit
- Medical Proteomics Unit, Office for Research and Development, Faculty of Medicine Siriraj Hospital, Mahidol University, 6th Floor - SiMR Building, 2 Wanglang Road, Bangkoknoi, Bangkok, 10700, Thailand
| | - Paleerath Peerapen
- Medical Proteomics Unit, Office for Research and Development, Faculty of Medicine Siriraj Hospital, Mahidol University, 6th Floor - SiMR Building, 2 Wanglang Road, Bangkoknoi, Bangkok, 10700, Thailand
| | - Papapit Tuchinda
- Department of Dermatology, Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok, Thailand
| | - Kanokvalai Kulthanan
- Department of Dermatology, Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok, Thailand
| | - Visith Thongboonkerd
- Medical Proteomics Unit, Office for Research and Development, Faculty of Medicine Siriraj Hospital, Mahidol University, 6th Floor - SiMR Building, 2 Wanglang Road, Bangkoknoi, Bangkok, 10700, Thailand.
| |
Collapse
|
4
|
Katz JS, Chou DK, Christian TR, Das TK, Patel M, Singh SN, Wen Y. Emerging Challenges and Innovations in Surfactant-mediated Stabilization of Biologic Formulations. J Pharm Sci 2021; 111:919-932. [PMID: 34883096 DOI: 10.1016/j.xphs.2021.12.002] [Citation(s) in RCA: 19] [Impact Index Per Article: 4.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/06/2021] [Revised: 12/03/2021] [Accepted: 12/03/2021] [Indexed: 02/08/2023]
Abstract
Biologics may be subjected to various destabilizing conditions during manufacturing, transportation, storage, and use. Therefore, biologics must be appropriately formulated to meet their desired quality target product profiles. In the formulations of protein-based biologics, one critical component is surfactant. Polysorbate 80 and Polysorbate 20 remain the most commonly used surfactants. Surfactants can stabilize proteins through different mechanisms and help the proteins withstand destabilization stresses. However, the challenges associated with surfactants, for instance, impurities, degradation, and potential triggering of adverse immune responses, have been encountered. Therefore, there are continued efforts to develop novel surfactants to overcome these challenges associated with traditional surfactants. Meanwhile, surfactants have also found their use in formulations of newer and novel modalities, namely, antibody-drug conjugates, bispecific antibodies, and adeno-associated viruses (AAV). This review provides an updated in-depth discussion of surfactants in the above-mentioned areas, namely mechanism of action of surfactants, a critical review of challenges with surfactants and current mitigation approaches, and emerging technologies to develop novel surfactants. In addition, gaps, current mitigations, and future directions have been presented to trigger further discussion and research to facilitate the use and development of novel surfactants.
Collapse
Affiliation(s)
- Joshua S Katz
- Pharma Solutions R&D, International Flavors and Fragrances, Wilmington, DE 19803, USA.
| | - Danny K Chou
- Compassion BioSolution, LLC, Lomita, CA 90717, USA
| | | | - Tapan K Das
- Bristol Myers Squibb, Biologics Development, New Brunswick, NJ 08903, USA
| | - Mayank Patel
- Dosage Form Design and Development, BioPharmaceuticals Development, R&D, AstraZeneca, Gaithersburg, USA
| | - Shubhadra N Singh
- GlaxoSmithKline R&D, Biopharmaceutical Product Sciences, Collegeville, PA 19426, USA
| | - Yi Wen
- Lilly Research Laboratory, Eli Lilly and Company, Indianapolis, IN 46285, USA
| |
Collapse
|
5
|
Holmes JP, Peguero JA, Garland RC, North J, Young S, Brent LD, Joseph-Ridge N. Intravenous Cetirizine vs Intravenous Diphenhydramine for the Prevention of Hypersensitivity Infusion Reactions: Results of an Exploratory Phase 2 Study. JOURNAL OF INFUSION NURSING 2021; 44:315-322. [PMID: 34555839 PMCID: PMC8565502 DOI: 10.1097/nan.0000000000000444] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
Abstract
Pretreatment with antihistamines for the prevention of hypersensitivity infusion reactions is recommended for certain biologics and chemotherapies. Cetirizine is the first injectable second-generation antihistamine recently approved for acute urticaria. A randomized, exploratory phase 2 study evaluated intravenous (IV) cetirizine 10 mg versus IV diphenhydramine 50 mg as pretreatment in patients receiving an anti-CD20 agent or paclitaxel. In the overall population (N = 34) and an elderly subgroup (n = 21), IV cetirizine was as effective as IV diphenhydramine in preventing infusion reactions (primary outcome) and associated with less sedation at all time points, a shorter infusion center stay, and fewer treatment-related adverse events.
Collapse
Affiliation(s)
- Jarrod P. Holmes
- St. Joseph Health Cancer Center, Santa Rosa, California (Dr Holmes); Oncology Consultants PA, Department of Research, Houston, Texas (Dr Peguero); Baylor Scott & White Medical Center, Temple, Texas (Dr Garland); and TerSera Therapeutics, Deerfield, Illinois (Ms North and Drs Young, Brent, and Joseph-Ridge)
- Jarrod P. Holmes, MD, FACP, is a hematologist/oncologist and associate medical director of oncology for Northern California, Providence Medical Group, in Santa Rosa, California
- Julio A. Peguero, MD, is board certified in internal medicine and medical oncology and the director of research at Oncology Consultants in Houston, Texas
- R. Campbell Garland, DO, is a hematologist/oncologist at Baylor Scott & White Medical Center based in Central Texas
- Janine North, BS, is executive director of clinical development at TerSera Therapeutics, in Deerfield, Illinois
- Stacia Young, PharmD, BCOP, MBA, is director of oncology medical science liaisons at TerSera Therapeutics
- Lonnie D. Brent, PharmD, is vice president of medical affairs at TerSera Therapeutics
- Nancy Joseph-Ridge, MD, is executive vice president of research and development and chief medical officer at TerSera Therapeutics
| | - Julio A. Peguero
- St. Joseph Health Cancer Center, Santa Rosa, California (Dr Holmes); Oncology Consultants PA, Department of Research, Houston, Texas (Dr Peguero); Baylor Scott & White Medical Center, Temple, Texas (Dr Garland); and TerSera Therapeutics, Deerfield, Illinois (Ms North and Drs Young, Brent, and Joseph-Ridge)
- Jarrod P. Holmes, MD, FACP, is a hematologist/oncologist and associate medical director of oncology for Northern California, Providence Medical Group, in Santa Rosa, California
- Julio A. Peguero, MD, is board certified in internal medicine and medical oncology and the director of research at Oncology Consultants in Houston, Texas
- R. Campbell Garland, DO, is a hematologist/oncologist at Baylor Scott & White Medical Center based in Central Texas
- Janine North, BS, is executive director of clinical development at TerSera Therapeutics, in Deerfield, Illinois
- Stacia Young, PharmD, BCOP, MBA, is director of oncology medical science liaisons at TerSera Therapeutics
- Lonnie D. Brent, PharmD, is vice president of medical affairs at TerSera Therapeutics
- Nancy Joseph-Ridge, MD, is executive vice president of research and development and chief medical officer at TerSera Therapeutics
| | - R. Campbell Garland
- St. Joseph Health Cancer Center, Santa Rosa, California (Dr Holmes); Oncology Consultants PA, Department of Research, Houston, Texas (Dr Peguero); Baylor Scott & White Medical Center, Temple, Texas (Dr Garland); and TerSera Therapeutics, Deerfield, Illinois (Ms North and Drs Young, Brent, and Joseph-Ridge)
- Jarrod P. Holmes, MD, FACP, is a hematologist/oncologist and associate medical director of oncology for Northern California, Providence Medical Group, in Santa Rosa, California
- Julio A. Peguero, MD, is board certified in internal medicine and medical oncology and the director of research at Oncology Consultants in Houston, Texas
- R. Campbell Garland, DO, is a hematologist/oncologist at Baylor Scott & White Medical Center based in Central Texas
- Janine North, BS, is executive director of clinical development at TerSera Therapeutics, in Deerfield, Illinois
- Stacia Young, PharmD, BCOP, MBA, is director of oncology medical science liaisons at TerSera Therapeutics
- Lonnie D. Brent, PharmD, is vice president of medical affairs at TerSera Therapeutics
- Nancy Joseph-Ridge, MD, is executive vice president of research and development and chief medical officer at TerSera Therapeutics
| | - Janine North
- St. Joseph Health Cancer Center, Santa Rosa, California (Dr Holmes); Oncology Consultants PA, Department of Research, Houston, Texas (Dr Peguero); Baylor Scott & White Medical Center, Temple, Texas (Dr Garland); and TerSera Therapeutics, Deerfield, Illinois (Ms North and Drs Young, Brent, and Joseph-Ridge)
- Jarrod P. Holmes, MD, FACP, is a hematologist/oncologist and associate medical director of oncology for Northern California, Providence Medical Group, in Santa Rosa, California
- Julio A. Peguero, MD, is board certified in internal medicine and medical oncology and the director of research at Oncology Consultants in Houston, Texas
- R. Campbell Garland, DO, is a hematologist/oncologist at Baylor Scott & White Medical Center based in Central Texas
- Janine North, BS, is executive director of clinical development at TerSera Therapeutics, in Deerfield, Illinois
- Stacia Young, PharmD, BCOP, MBA, is director of oncology medical science liaisons at TerSera Therapeutics
- Lonnie D. Brent, PharmD, is vice president of medical affairs at TerSera Therapeutics
- Nancy Joseph-Ridge, MD, is executive vice president of research and development and chief medical officer at TerSera Therapeutics
| | - Stacia Young
- St. Joseph Health Cancer Center, Santa Rosa, California (Dr Holmes); Oncology Consultants PA, Department of Research, Houston, Texas (Dr Peguero); Baylor Scott & White Medical Center, Temple, Texas (Dr Garland); and TerSera Therapeutics, Deerfield, Illinois (Ms North and Drs Young, Brent, and Joseph-Ridge)
- Jarrod P. Holmes, MD, FACP, is a hematologist/oncologist and associate medical director of oncology for Northern California, Providence Medical Group, in Santa Rosa, California
- Julio A. Peguero, MD, is board certified in internal medicine and medical oncology and the director of research at Oncology Consultants in Houston, Texas
- R. Campbell Garland, DO, is a hematologist/oncologist at Baylor Scott & White Medical Center based in Central Texas
- Janine North, BS, is executive director of clinical development at TerSera Therapeutics, in Deerfield, Illinois
- Stacia Young, PharmD, BCOP, MBA, is director of oncology medical science liaisons at TerSera Therapeutics
- Lonnie D. Brent, PharmD, is vice president of medical affairs at TerSera Therapeutics
- Nancy Joseph-Ridge, MD, is executive vice president of research and development and chief medical officer at TerSera Therapeutics
| | - Lonnie D. Brent
- St. Joseph Health Cancer Center, Santa Rosa, California (Dr Holmes); Oncology Consultants PA, Department of Research, Houston, Texas (Dr Peguero); Baylor Scott & White Medical Center, Temple, Texas (Dr Garland); and TerSera Therapeutics, Deerfield, Illinois (Ms North and Drs Young, Brent, and Joseph-Ridge)
- Jarrod P. Holmes, MD, FACP, is a hematologist/oncologist and associate medical director of oncology for Northern California, Providence Medical Group, in Santa Rosa, California
- Julio A. Peguero, MD, is board certified in internal medicine and medical oncology and the director of research at Oncology Consultants in Houston, Texas
- R. Campbell Garland, DO, is a hematologist/oncologist at Baylor Scott & White Medical Center based in Central Texas
- Janine North, BS, is executive director of clinical development at TerSera Therapeutics, in Deerfield, Illinois
- Stacia Young, PharmD, BCOP, MBA, is director of oncology medical science liaisons at TerSera Therapeutics
- Lonnie D. Brent, PharmD, is vice president of medical affairs at TerSera Therapeutics
- Nancy Joseph-Ridge, MD, is executive vice president of research and development and chief medical officer at TerSera Therapeutics
| | - Nancy Joseph-Ridge
- Corresponding Authors: Nancy Joseph-Ridge, MD, 520 Lake Cook Rd, Suite 500, Deerfield, IL 60015 () and Lonnie D. Brent, PharmD, 520 Lake Cook Rd, Suite 500, Deerfield, IL 60015 ()
| |
Collapse
|
6
|
Wang Y, Tan X, Fan X, Zhao L, Wang S, He H, Yin T, Zhang Y, Tang X, Jian L, Jin J, Gou J. Current strategies for oral delivery of BCS IV drug nanocrystals: challenges, solutions and future trends. Expert Opin Drug Deliv 2021; 18:1211-1228. [PMID: 33719798 DOI: 10.1080/17425247.2021.1903428] [Citation(s) in RCA: 8] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/04/2023]
Abstract
INTRODUCTION Oral absorption of BCS IV drug benefits little from improved dissolution. Therefore, the absorption of BCS IV drug nanocrystals 'as a whole' strategy is preferred, and structural modification of nanocrystals is required. Surface modification helps the nanocrystals maintain particle structure before drug dissolution is needed, thus enhancing the oral absorption of BCS IV drugs and promoting therapeutic effect. Here, the main challenges and solutions of oral BCS IV drug nanocrystals delivery are discussed. Moreover, strategies for nanocrystal surface modification that facilitates oral bioavailability of BCS IV drugs are highlighted, and provide insights for the innovation in oral drug delivery. AREAS COVERED Promising size, shape, and surface modification of nanocrystals have gained interests for application in oral BCS IV drugs. EXPERT OPINION Nanocrystal surface modification is a feasible method to maintain the structural integrity of nanocrystals, and the introduced materials can also be modified to integrate additional functions to further facilitate the absorption of nanocrystals. It is expected that the absorption 'as a whole' strategy of nanocrystals will provide different choices for the oral BCS IV drugs.
Collapse
Affiliation(s)
- Yue Wang
- Department of Pharmaceutics, Shenyang Pharmaceutical University, Shenyang, China.,Department of Pharmaceutics, School of Pharmacy, Jilin University, Changchun, China
| | - Xinyi Tan
- Department of Pharmaceutics, Shenyang Pharmaceutical University, Shenyang, China
| | - Xinyu Fan
- Department of Pharmacy, Shengjing Hospital of China Medical University, Shenyang, China
| | - Linxuan Zhao
- Department of Pharmaceutics, Shenyang Pharmaceutical University, Shenyang, China.,Department of Pharmaceutics, School of Pharmacy, Jilin University, Changchun, China
| | - Shuhang Wang
- Department of Pharmaceutics, Shenyang Pharmaceutical University, Shenyang, China.,Department of Pharmaceutics, School of Pharmacy, Jilin University, Changchun, China
| | - Haibing He
- Department of Pharmaceutics, Shenyang Pharmaceutical University, Shenyang, China
| | - Tian Yin
- School of Functional Food and Wine, Shenyang Pharmaceutical University, Shenyang, China
| | - Yu Zhang
- Department of Pharmaceutics, Shenyang Pharmaceutical University, Shenyang, China
| | - Xing Tang
- Department of Pharmaceutics, Shenyang Pharmaceutical University, Shenyang, China
| | - Lingyan Jian
- Department of Pharmacy, Shengjing Hospital of China Medical University, Shenyang, China
| | - Jian Jin
- Jiangsu Key Laboratory of Marine Biological Resources and Environment, Jiangsu Key Laboratory of Marine Pharmaceutical Compound Screening, School of Pharmacy, Jiangsu Ocean University, Lianyungang, China
| | - Jingxin Gou
- Department of Pharmaceutics, Shenyang Pharmaceutical University, Shenyang, China
| |
Collapse
|